These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19147089)

  • 21. Mast cell burden and reticulin fibrosis in the myeloproliferative neoplasms: a computer-assisted image analysis study.
    Ahmed A; Powers MP; Youker KA; Rice L; Ewton A; Dunphy CH; Chang CC
    Pathol Res Pract; 2009; 205(9):634-8. PubMed ID: 19446406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
    Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in understanding myelofibrosis and essential thrombocythemia.
    Vainchenker W; Constantinescu SN; Plo I
    F1000Res; 2016; 5():. PubMed ID: 27134742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
    Garber K
    J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
    [No Abstract]   [Full Text] [Related]  

  • 25. Classic myeloproliferative neoplasms in Singapore: A population-based study on incidence, trends, and survival from 1968 to 2017.
    Htun HL; Lian W; Wong J; Tan EJ; Foo LL; Ong KH; Lim WY
    Cancer Epidemiol; 2022 Aug; 79():102175. PubMed ID: 35569302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deactylase inhibition in myeloproliferative neoplasms.
    Mithraprabhu S; Grigoriadis G; Khong T; Spencer A
    Invest New Drugs; 2010 Dec; 28 Suppl 1(Suppl 1):S50-7. PubMed ID: 21127942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The history of myeloproliferative disorders: before and after Dameshek.
    Tefferi A
    Leukemia; 2008 Jan; 22(1):3-13. PubMed ID: 17882283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inheritance of the chronic myeloproliferative neoplasms. A systematic review.
    Ranjan A; Penninga E; Jelsig AM; Hasselbalch HC; Bjerrum OW
    Clin Genet; 2013 Feb; 83(2):99-107. PubMed ID: 23094849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atypical myeloproliferative disorders: diagnosis and management.
    Tefferi A; Elliott MA; Pardanani A
    Mayo Clin Proc; 2006 Apr; 81(4):553-63. PubMed ID: 16610578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New molecular markers within the chronic myeloproliferative disorders. I: the PRV-1 gene].
    Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
    Ugeskr Laeger; 2006 Sep; 168(39):3295-9. PubMed ID: 17032591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytogenetics of myeloproliferative neoplasms.
    Campbell LJ
    Methods Mol Biol; 2011; 730():89-98. PubMed ID: 21431636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of Total Antioxidant Capacity, 8-Hydroxy-2'-deoxy-guanosine, the Genetic Landscape, and Their Associations in
    Găman MA; Mambet C; Neagu AI; Bleotu C; Gurban P; Necula L; Botezatu A; Ataman M; Diaconu CC; Ionescu BO; Ghiaur AE; Tatic A; Coriu D; Găman AM; Diaconu CC
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Chronic myeloid neoplasms. Diagnostic criteria and current therapeutic concepts].
    Schmitt-Graeff AH
    Pathologe; 2010 Feb; 31(1):29-41. PubMed ID: 20076959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myeloproliferative disorders.
    Bench AJ; Cross NC; Huntly BJ; Nacheva EP; Green AR
    Best Pract Res Clin Haematol; 2001 Sep; 14(3):531-51. PubMed ID: 11640868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An inhibitor of Janus kinase 2 prevents polycythemia in mice.
    Mathur A; Mo JR; Kraus M; O'Hare E; Sinclair P; Young J; Zhao S; Wang Y; Kopinja J; Qu X; Reilly J; Walker D; Xu L; Aleksandrowicz D; Marshall G; Scott ML; Kohl NE; Bachman E
    Biochem Pharmacol; 2009 Aug; 78(4):382-9. PubMed ID: 19413997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncogenic and tumor suppressor genes expression in myeloproliferative neoplasms: The hidden side of a complex pathology.
    Abedi E; Karimi M; Yaghobi R; Mohammadi H; Haghpanah S; Moghadam M; Bayat E; Rezvani A; Ramzi M
    J Clin Lab Anal; 2022 Apr; 36(4):e24289. PubMed ID: 35176183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?
    Hasselbalch HC
    Leuk Res; 2009 Jan; 33(1):11-8. PubMed ID: 18632152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clonal evolution of 8p11 stem cell syndrome in a 14-year-old Chinese boy: a review of literature of t(8;13) associated myeloproliferative diseases.
    Wong WS; Cheng KC; Lau KM; Chan NP; Shing MM; Cheng SH; Chik KW; Li CK; Ng MH
    Leuk Res; 2007 Feb; 31(2):235-8. PubMed ID: 16777224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Shooting the messenger: targeting signal transduction pathways in leukemia and related disorders.
    Noor SM; Bell R; Ward AC
    Crit Rev Oncol Hematol; 2011 Apr; 78(1):33-44. PubMed ID: 20570172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors.
    Nand R; Bryke C; Kroft SH; Divgi A; Bredeson C; Atallah E
    Leuk Res; 2009 Aug; 33(8):1144-6. PubMed ID: 19394693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.